Onconic Therapeutics Inc (476060)

Currency in KRW
21,500
+250(+1.18%)
Closed·
Earnings results expected in 13 days
476060 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
21,35022,650
52 wk Range
5,00065,200
Key Statistics
Bid/Ask
21,450.00 / 21,500.00
Prev. Close
21,250
Open
21,750
Day's Range
21,350-22,650
52 wk Range
5,000-65,200
Volume
284.86K
Average Volume (3m)
1.04M
1-Year Change
282.2222%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
476060 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12,500
Downside
-41.86%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 12,500
(-41.86% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Mar 13, 2026
EPS / Forecast
-- / --
Revenue / Forecast
16.2B / 15B
EPS Revisions
Last 90 days

476060 Income Statement

Compare 476060 to Peers and Sector

Metrics to compare
476060
Peers
Sector
Relationship
P/E Ratio
61.1x−10.3x−0.5x
PEG Ratio
-−0.240.00
Price/Book
13.4x2.4x2.6x
Price / LTM Sales
18.1x9.7x3.3x
Upside (Analyst Target)
−41.9%133.2%47.1%
Fair Value Upside
Unlock−0.5%6.2%Unlock

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Korea.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
10.66K0.02%229.15M
Other Institutional Investors
27.14M60.47%583.56B
Public Companies & Retail Investors
17.73M39.51%381.30B
Total
44.89M100.00%965.09B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Jeil Pharmaceutical Co.,Ltd44.56%20,000,000430,000,000
S&P Innovation Technology No. 1 Association3.95%1,773,60038,132,400

People Also Watch

294,000
010120
+5.76%
983,000
079550
+4.46%
147,700
069620
-0.40%
1,629,000
010130
+3.17%
445,000
128940
-3.26%

FAQ

What Is the Onconic Therapeutics (476060) Stock Price Today?

The Onconic Therapeutics stock price today is 21,500 KRW.

What Stock Exchange Does Onconic Therapeutics Trade On?

Onconic Therapeutics is listed and trades on the KOSDAQ.

What Is the Stock Symbol for Onconic Therapeutics?

The stock symbol for Onconic Therapeutics is "476060."

What Is the Onconic Therapeutics Market Cap?

As of today, Onconic Therapeutics market cap is 965.09B KRW.

When Is the Next Onconic Therapeutics Earnings Date?

Onconic Therapeutics will release its next earnings report on May 18, 2026.

From a Technical Analysis Perspective, Is 476060 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Onconic Therapeutics Stock Split?

Onconic Therapeutics has split 2 times.

What is the current trading status of Onconic Therapeutics (476060)?

As of May 05, 2026, Onconic Therapeutics (476060) is trading at a price of 21,500 KRW, with a previous close of 21,250 KRW. The stock has fluctuated within a day range of 21,350 KRW to 22,650 KRW, while its 52-week range spans from 5,000 KRW to 65,200 KRW.

What Is Onconic Therapeutics (476060) Price Target According to Analysts?

The average 12-month price target for Onconic Therapeutics is 12,500 KRW, with a high estimate of 12500 KRW and a low estimate of 12500 KRW. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an -41.86% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.